Kala Bio

KALA BIO develops treatments for rare eye diseases. Its main therapy aims to help people with persistent corneal defects. The company’s work targets patients with limited options for eye care.

Eyeing the Details: Products and Services

• KPI-012 (Lead Therapy): Investigational treatment for persistent corneal epithelial defects, targeting patients with severe front-of-eye conditions. (0% of revenue, as no product sales)
• KPI-014 (Preclinical Program): Early-stage therapy for inherited retinal diseases, aimed at rare genetic eye disorders. (0% of revenue)
• Former Commercial Products: EYSUVIS and INVELTYS, both for eye inflammation, sold to Alcon in 2022. (No current revenue contribution)
• AMPPLIFY Technology: Nanoparticle-based drug delivery system, previously used in commercial eye products. (No current revenue)

Growth Spurts and Strategic Moves

• Sold commercial eye products to Alcon in July 2022, shifting focus to clinical development.
• Acquired Combangio in 2021, adding KPI-012 to its pipeline.
• Secured a $15 million grant from the California Institute for Regenerative Medicine in 2023 to support KPI-012.
• Completed patient enrollment for KPI-012 Phase 2b trial in July 2025 across 37 sites in the US and Latin America.

What Makes Kala Bio Stand Out

KALA BIO uses a unique nanoparticle technology to deliver drugs to the eye. Its therapies focus on rare diseases with few existing treatments. The company relies on partnerships and grant funding to advance its pipeline.

Five Things You Need to Know

• Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
• Net loss was $11 million in Q2 2025, up 16.5% from Q2 2024.
• Cash and cash equivalents were $31.9 million as of June 30, 2025.
• Operating expenses rose to $11 million in Q2 2025, up 14.8% year-over-year.

Bottom Line

KALA BIO has shifted from commercial sales to clinical research in rare eye diseases. Its future depends on advancing new therapies and securing additional funding.